Expression of transforming growth factor-β1 (TGF-β1) and E-cadherin in glioma

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1477-1484

  Yang, Liu ^a   Liu, Mei ^a   Deng, Chuanzong ^a   Gu, Zhikai ^a   Gao, Yilu ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Differentiation; E cadherin; Glioma; Metastasis; siRNA; TGF 1

Indexed keywords

MESSENGER RNA; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ARTICLE; BRAIN TISSUE; CANCER PATIENT; CANCER TISSUE; CARCINOGENESIS; CELL INVASION; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOMA; GLIOMA CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SCHOOL CHILD; TUMOR DIFFERENTIATION; UPREGULATION; WESTERN BLOTTING;

EID: 84868134234     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0398-z     Document Type: Article

References (39)

1. Iwami K, Natsume A, Wakabayashi T. Cytokine networks in glioma. Neurosurg Rev. 2011;34(3):253-63.
2. Rainov NG, Heidecke V. Clinical development of experimental therapies for malignant glioma. Sultan Qaboos Univ Med J. 2011;11(1):5-28.
3. Kros JM. Grading of gliomas: the road from eminence to evidence. J Neuropathol Exp Neurol. 2011;70(2):101-9.
4. Sasine JP, Savaraj N, Feun LG. Topoisomerase I inhibitors in the treatment of primary CNS malignancies: an update on recent trends. Anticancer Agents Med Chem. 2010;10(9):683-96.
5. Strik HM, Kolodziej M, Oertel W, Basecke J. Glycobiology in malignant gliomas: expression and functions of galectins and possible therapeutic options. Curr Pharm Biotechnol 2011.
6. Hdeib A, Sloan AE. Convection-enhanced delivery of (131)I-chTNT-1/B mAB for treatment of high-grade adult gliomas. Expert Opin Biol Ther. 2011;11(6):799-806.
7. Patnaik S, Mallick R, Yendamuri S. MicroRNAs and esophageal cancer. J Gastrointest Oncol. 2010;1(1):55-63.
8. Plaas A, Velasco J, Gorski DJ, Li J, Cole A, Christopherson K, Sandy JD. The relationship between fibrogenic TGFbeta1 signaling in the joint and cartilage degradation in post-injury osteoarthritis. Osteoarthritis Cartilage 2011.
9. Yang SY, Miah A, Pabari A, Winslet M. Growth factors and their receptors in cancer metastases. Front Biosci. 2011;16:531-8.
10. Pardali E, ten Dijke P. Transforming growth factor-beta signaling and tumor angiogenesis. Front Biosci. 2009;14:4848-61.
11. Hinck AP, O'Connor-McCourt MD. Structures of TGF-beta receptor complexes: implications for function and therapeutic intervention using ligand traps. Curr Pharm Biotechnol 2011.
12. Hau P, Jachimczak P, Schlaier J, Bogdahn U. TGF-beta2 signaling in high-grade gliomas. Curr Pharm Biotechnol 2011.
13. Di C, Mattox AK, Harward S, Adamson C. Emerging therapeutic targets and agents for glioblastoma migrating cells. Anticancer Agents Med Chem. 2011;10(7):543-55.
14. You S, Alyanakian MA, Segovia B, Damotte D, Bluestone J, Bach JF, Chatenoud L. Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Ann N Y Acad Sci. 2008;1150:300-10.
15. Cavallaro U, Dejana E. Adhesion molecule signalling: not always a sticky business. Nat Rev Mol Cell Biol. 2011;12(3):189-97.
16. Xiao D, He J. Epithelial mesenchymal transition and lung cancer. J Thorac Dis. 2010;2(3):154-9.
17. Pan J, Yang M. The role of epithelial-mesenchymal transition in pancreatic cancer. J Gastrointest Oncol. 2011;2(3):151-6.
18. Wang J, Li LC. Small RNA and its application in andrology and urology. Transl Androl Urol. 2012;1(1):33-43.
19. Herfs M, Hubert P, Kholod N, Caberg JH, Gilles C, Berx G, Savagner P, Boniver J, Delvenne P. Transforming growth factor-beta1-mediated Slug and Snail transcription factor up-regulation reduces the density of Langerhans cells in epithelial metaplasia by affecting E-cadherin expression. Am J Pathol. 2008;172(5):1391-402.
20. Chamberlain MC. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother. 2010;10(10):1537-44.
21. Schiffer D, Annovazzi L, Caldera V, Mellai M. On the origin and growth of gliomas. Anticancer Res. 2010;30(6):1977-98.
22. Sciume G, Santoni A, Bernardini G. Chemokines and glioma: invasion and more. J Neuroimmunol. 2010;224(1-2):8-12.
23. Sherman JH, Hoes K, Marcus J, Komotar RJ, Brennan CW, Gutin PH. Neurosurgery for brain tumors: update on recent technical advances. Curr Neurol Neurosci Rep. 2011;11(3):313-9.
24. Prager GW, Poettler M, Unseld M, Zielinski CC. Angiogenesis in cancer: anti-VEGF escape mechanisms. Transl Lung Cancer Res. 2012;1(1):14-25.
25. Candolfi M, Kroeger KM, Muhammad AK, Yagiz K, Farrokhi C, Pechnick RN, Lowenstein PR, Castro MG. Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr Gene Ther. 2009;9(5):409-21.
26. Schor AM, Schor SL. Angiogenesis and tumour progression: migration-stimulating factor as a novel target for clinical intervention. Eye (Lond). 2010;24(3):450-8.
27. Glick AB, Perez-Lorenzo R, Mohammed J. Context-dependent regulation of cutaneous immunological responses by TGFbeta1 and its role in skin carcinogenesis. Carcinogenesis. 2008;29(1):9-14.
28. Li AG, Lu SL, Han G, Kulesz-Martin M, Wang XJ. Current view of the role of transforming growth factor beta 1 in skin carcinogenesis. J Investig Dermatol Symp Proc. 2005;10(2):110-7.
29. Soufla G, Sifakis S, Baritaki S, Zafiropoulos A, Koumantakis E, Spandidos DA. VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett. 2005;221(1):105-18.
30. Johnson C, Han YY, Nathan H, McCarra J, Alpini G, Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer. 2012;1(1):58-70.
31. Bellone G, Carbone A, Tibaudi D, Mauri F, Ferrero I, Smirne C, Suman F, Rivetti C, Migliaretti G, Camandona M, et al. Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma. Eur J Cancer. 2001;37(2):224-33.
32. Djaborkhel R, Tvrdik D, Eckschlager T, Raska I, Muller J. Cyclin A down-regulation in TGFbeta1-arrested follicular lymphoma cells. Exp Cell Res. 2000;261(1):250-9.
33. Shariat SF, Kim JH, Andrews B, Kattan MW, Wheeler TM, Kim IY, Lerner SP, Slawin KM. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001;92(12):2985-92.
34. Sulzer MA, Leers MP, van Noord JA, Bollen EC, Theunissen PH. Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1319-23.
35. Zigler M, Dobroff AS, Bar-Eli M. Cell adhesion: implication in tumor progression. Minerva Med. 2010;101(3):149-62.
36. Mikheeva SA, Mikheev AM, Petit A, Beyer R, Oxford RG, Khorasani L, Maxwell JP, Glackin CA, Wakimoto H, Gonzalez-Herrero I, et al. TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer. 2010;9:194.
37. Hills CE, Squires PE. TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol. 2010;31(1):68-74.
38. Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res. 2004;10(12 Pt 1):4125-33.
39. Takano S, Kanai F, Jazag A, Ijichi H, Yao J, Ogawa H, Enomoto N, Omata M, Nakao A. Smad4 is essential for down-regulation of E-cadherin induced by TGF-beta in pancreatic cancer cell line PANC-1. J Biochem. 2007;141(3):345-51.